Death receptor ligands in tumors

被引:23
作者
Cappello, P
Novelli, F
Forni, G [1 ]
Giovarelli, M
机构
[1] Univ Turin, Dept Clin & Biol Sci, I-10043 Orbassano, Italy
[2] Osped San Giovanni Battista Torino, Ctr Ric Med Sperimentale, Turin, Italy
关键词
apoptosis; death receptor ligands; death receptors; tumor counterattack;
D O I
10.1097/00002371-200201000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of apoptosis via death receptors is a tightly regulated event, and the death pathway itself is open to interference on the part of soluble or membrane-bound decoy receptors. The aggregation state of the death-inducing ligand is a crucial factor, particularly when these molecules are used as recombinant drugs against tumors. Whether tumors are sensitive to such ligands is determined by both the net abundance of death receptors versus decoy receptors and the balance between intracellular apoptotic and antiapoptotic mechanisms. This means that in vivo elimination of tumor cells by effector arms such as T lymphocytes, natural killer cells, macrophages, and dendritic cells is dependent on both the function of activated lymphoid cells and the genetic properties of tumor cells. Death receptor ligands, however, may be a double-edged sword. When. expressed on cytotoxic T lymphocytes, natural killer cells, monocytes, and dendritic cells, they induce the apoptosis of many tumor cells, whereas their expression on tumor cells induces the apoptosis of killer cells. The in vivo result is influenced by the number of infiltrating cells, their state of activation, the cytokine repertoire in the tumor microenvironment, and the ability of the tumor to produce soluble factors inhibiting their cytolytic functions.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 206 条
[1]   TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention [J].
Ahmad, M ;
Shi, YF .
ONCOGENE, 2000, 19 (30) :3363-3371
[2]   Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts [J].
Allison, J ;
Georgiou, HM ;
Strasser, A ;
Vaux, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3943-3947
[3]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[4]   Inhibition of the alloantibody response by CD95 ligand [J].
Arai, H ;
Chan, SY ;
Bishop, DK ;
Nabel, GJ .
NATURE MEDICINE, 1997, 3 (08) :843-848
[5]   MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40 [J].
ARMITAGE, RJ ;
FANSLOW, WC ;
STROCKBINE, L ;
SATO, TA ;
CLIFFORD, KN ;
MACDUFF, BM ;
ANDERSON, DM ;
GIMPEL, SD ;
DAVISSMITH, T ;
MALISZEWSKI, CR ;
CLARK, EA ;
SMITH, CA ;
GRABSTEIN, KH ;
COSMAN, D ;
SPRIGGS, MK .
NATURE, 1992, 357 (6373) :80-82
[6]   Apoptosis control by death and decoy receptors [J].
Ashkenazi, A ;
Dixit, VM .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :255-260
[7]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[8]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[9]   IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity in vivo [J].
Aung, S ;
Graham, BS .
JOURNAL OF IMMUNOLOGY, 2000, 164 (07) :3487-3493
[10]  
BAUM PR, 1994, CIRC SHOCK, V44, P30